CLX

CLOROX CO /DE/
3 filings tracked
consumer stapleshousehold productsLARGE ($10B-200B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

The investment narrative has shifted from a broad consumer staples play to a focused bet on a structural turnaround. By divesting non-core assets and integrating GOJO, Clorox is attempting to build a more resilient, high-margin hygiene and cleaning platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Conversely, the financial data reveals a concerning trend of deteriorating liquidity and operational friction.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CLX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Clorox is currently navigating a high-stakes transition, attempting to pivot from a period of operational instability toward a leaner, more focused portfolio.…

Latest Available Quarter (Q2 '26 (10-Q))

Core Takeaway

Clorox is exiting non-core businesses to focus on essentials, but is doing so with a strained balance sheet.

Investor Lens

The trade-off is between a leaner, more efficient future and the immediate risk of a cash crunch.

Watch Next

Quarterly operating cash flow and the progress of ERP-driven cost savings.

Calculated Financial Trajectory (Click to filter signals)

Revenue / Net Sales$1670M
the quarter ended December 31, '25: $1673Mthe quarter ended March 31, '26: $1670M
Net Income / Loss$187M
the quarter ended December 31, '25: $157Mthe quarter ended March 31, '26: $187M

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)0.00Q1 '26 (10-Q)-0.10Q2 '26 (10-Q)

Signal Timeline

bearishApr 30

Gross margins fell 200 basis points over nine months due to operational failures.

margin compression
80%
bullishApr 30

Completed acquisition of GOJO to strengthen hygiene portfolio.

acquisition
60%
bullishApr 30

Exited the Better Health VMS business to focus on core essentials.

divestiture
50%
bearishApr 30

Increased reliance on short-term debt and delayed-draw term loans.

debt restructure
70%

Filing History

10-QApr 30, 2026
Expand Sequence

The latest filing presents a company at a critical crossroads, attempting to engineer a margin recovery while managing a tightening liquidity profile. While the completion of the ERP rollout and the GOJO acquisition provide a roadmap for future efficiency, the immediate financial data reveals a struggle to convert sales into sustainable cash flow. The tension between aggressive capital returns and a growing debt load creates a high-stakes environment for investors. Ultimately, the impact of this filing is a shift in the investment lens from simple growth to a question of solvency and execution. The company's ability to stabilize its manufacturing base and realize the promised synergies from its new technology stack will be the primary determinants of its success. Investors must now weigh the potential for a high-margin recovery against the immediate risks of a liquidity squeeze and macroeconomic volatility.

10-QFeb 3, 2026
Expand Sequence

The latest 10-Q reveals a company at a critical crossroads, trading short-term volume stability for a long-term structural overhaul. While the acquisition of GOJO and the exit from VMS align the business with its core competencies, the financial cost of this transition is reflected in increased interest expenses and a heavy debt burden. The company is effectively betting that a leaner cost structure and digital transformation will offset current revenue headwinds. Investors are now weighing the potential for a high-margin recovery against the immediate risks of a liquidity crunch. The success of the investment thesis depends on whether the GOJO integration can spark a volume rebound and if the ERP rollout can deliver efficiencies without further draining cash reserves. The tension between aggressive shareholder returns and necessary capital expenditures remains the central theme for the stock.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.